Deep Learning In Drug Discovery And Diagnostics Market Report 2026

Deep Learning In Drug Discovery And Diagnostics Market Overview

• Deep Learning In Drug Discovery And Diagnostics market size has reached to $10.58 billion in 2025 • Expected to grow to $36.96 billion in 2030 at a compound annual growth rate (CAGR) of 28.4% • Growth Driver: Rising Demand For Personalized Medicine Fuels Growth In Deep Learning In Drug Discovery And Diagnostics • Market Trend: Advancing Drug Discovery Through Artificial Intelligence (AI)-Driven Automation • North America was the largest region in 2025.

What Is Covered Under Deep Learning In Drug Discovery And Diagnostics Market?

Deep learning in drug discovery and diagnostics refers to the use of advanced neural networks and artificial intelligence (AI) techniques to analyze complex biological and chemical data for predicting drug interactions, identifying disease patterns, and enhancing personalized medicine. Deep learning enhances drug discovery and diagnostics by improving prediction accuracy, automating data processing, and enabling personalized medicine through advanced analysis of complex biological and chemical data. The main types of deep learning in drug discovery and diagnostics are drug discovery, diagnostics, forensic interventions, and others. Drug discovery involves using deep learning algorithms to analyze biological data and predict which drug compounds will be effective. These algorithms can speed up the process by identifying promising drug candidates and potential side effects earlier in the research phase. The drug types are small-molecule drugs and biologic drugs, and they are used by various end-use industries such as pharmaceutical companies, biotechnology companies, contract research organizations (CROs), and healthcare information technology (IT).

What Is The Deep Learning In Drug Discovery And Diagnostics Market Growth Forecast?

The deep learning in drug discovery and diagnostics market size is expected to see exponential growth in the next few years. It will grow to $36.96 billion in 2030 at a compound annual growth rate (CAGR) of 28.4%. The growth in the forecast period can be attributed to increasing investments in ai-based healthcare solutions, rising demand for precision medicine, expansion of ai adoption across clinical workflows, growing use of real-world evidence data, increasing regulatory acceptance of ai-assisted diagnostics. Major trends in the forecast period include increasing adoption of deep neural networks in drug screening, rising use of AI-driven predictive modeling in diagnostics, growing integration of multi-omics data analysis, expansion of automated clinical decision support systems, enhanced focus on personalized medicine platforms.

Global Deep Learning In Drug Discovery And Diagnostics Market Segmentation

1) By Type: Drug Discovery, Diagnostics, Forensic Interventions, Other Types 2) By Drug Type: Small Molecule Drugs, Biologics Drugs 3) By End Use Industry: Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations (CROs), Healthcare Information Technology (IT) Subsegments: 1) By Drug Discovery: Target Identification, Drug Screening, Lead Optimization, Predictive Modeling 2) By Diagnostics: Medical Imaging Analysis, Genomic Data Interpretation, Disease Detection Algorithms, Personalized Medicine 3) By Forensic Interventions: Digital Pathology, Forensic DNA Analysis, Toxicology Screening, Crime Scene Reconstruction 4) By Other Types: Biomarker Discovery, Predictive Analytics in Healthcare, Patient Data Management Systems

What Is The Driver Of The Deep Learning In Drug Discovery And Diagnostics Market?

The growing demand for personalized medicine is expected to propel the growth of deep learning in drug discovery and diagnostics market going forward. Personalized medicine tailors medical treatment and interventions to individual genetic, environmental, and lifestyle factors to optimize efficacy and minimize side effects. The growing demand for personalized medicine is driven by advancements in genomics and data analytics, which enable more precise and effective treatments based on individual patient profiles. Deep learning in drug discovery and diagnostics enhances personalized medicine by analyzing complex biological data to identify unique biomarkers and predict patient responses to treatments more accurately. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, compared to six in 2022. Therefore, the growing demand for personalized medicine drives deep learning in drug discovery and diagnostics industry.

Key Players In The Global Deep Learning In Drug Discovery And Diagnostics Market

Major companies operating in the deep learning in drug discovery and diagnostics market are Google Inc., Microsoft Corporation, International Business Machines Corporation, NVIDIA Corporation, Zebra Medical Vision Ltd, Tempus Labs Inc., Nanostring Technologies Inc., Owkin Inc., Insilico Medicine Inc., SOPHiA GENETICS SA, Qureai Technologies Pvt Ltd, H2Oai Inc., Arterys Inc., Deep Genomics Inc., GNS Healthcare Inc., MedAware Systems Inc., PathAI Inc., Kheiron Medical Technologies Ltd, CureMetrix Inc., OncoImmunity AS, Proscia Inc., BenevolentAI Ltd, BioXcel Therapeutics Inc.

Global Deep Learning In Drug Discovery And Diagnostics Market Trends and Insights

Major companies operating in the deep learning in drug discovery and diagnostics market are incorporating advanced technologies such as generative artificial intelligence (AI) and machine-learning (ML)–driven automation platforms to improve efficiency, lower research and development (R&D) costs, and accelerate early-stage therapeutic discovery. Generative AI and ML-driven automation platforms refer to computational systems that learn from chemical and biological data to design new drug candidates in silico, predict molecular behavior, and automatically synthesize and test compounds using robotic systems, thereby reducing reliance on traditional high-throughput screening. For instance, in July 2024, Exscientia, a UK-based AI-driven drug-design company, launched its AWS-powered AI/ML platform, which integrates a “DesignStudio” for AI-based molecule generation with an “AutomationStudio” for robotic lab synthesis and testing. The platform operates in a closed “design–make–test–learn” loop, where experimental data continuously refines the AI models, significantly speeding up discovery, improving scalability, and enabling more precise and cost-effective development of novel therapeutics.

What Are Latest Mergers And Acquisitions In The Deep Learning In Drug Discovery And Diagnostics Market?

In February 2024, Ginkgo Bioworks Holdings Inc., a US-based biotech company that specializes in using genetic engineering acquired Reverie Labs key assets for an undisclosed amount. Through the acquisition of Reverie's infrastructure and software for training large-scale AI foundation models, Ginkgo aims to enhance its AI or ML-driven discovery services and accelerate its efforts to develop next-generation biological foundation models. Reverie Labs Inc. is a US-based company that built and used AI or ML tools to accelerate drug discovery.

Regional Outlook

North America was the largest region in the deep learning in drug discovery and diagnostics market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Deep Learning In Drug Discovery And Diagnostics Market?

The deep learning in drug discovery and diagnostics market consists of revenues earned by entities by providing services such as developing and integrating deep learning algorithms, analyzing large-scale biological and chemical data, offering software solutions and platforms, and consulting on AI-driven drug discovery and diagnostic strategies. The market value includes the value of related goods sold by the service provider or included within the service offering. The deep learning in drug discovery and diagnostics market also includes sales of software platforms and tools, machine learning frameworks, data analytics solutions, cloud-based computing services, hardware accelerators, and AI-driven diagnostic devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Deep Learning In Drug Discovery And Diagnostics Market Report 2026?

The deep learning in drug discovery and diagnostics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the deep learning in drug discovery and diagnostics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.